Preventing Cryptococcosis-Shifting the Paradigm in the Era of Highly Active Antiretroviral Therapy
about
HIV-Associated Cryptococcal Meningitis: Bridging the Gap Between Developed and Resource-Limited SettingsCryptococcal meningitis: A neglected NTD?Screening HIV-Infected Patients with Low CD4 Counts for Cryptococcal Antigenemia prior to Initiation of Antiretroviral Therapy: Cost Effectiveness of Alternative Screening Strategies in South AfricaComputational Analysis Reveals a Key Regulator of Cryptococcal Virulence and Determinant of Host ResponseCryptococcal Antigenemia in Nigerian Patients With Advanced Human Immunodeficiency Virus: Influence of Antiretroviral Therapy AdherenceAdvanced HIV disease in Botswana following successful antiretroviral therapy rollout: Incidence of and temporal trends in cryptococcal meningitis.Asymptomatic cryptococcal antigen prevalence detected by lateral flow assay in hospitalised HIV-infected patients in São Paulo, Brazil.Cryptococcal antigen screening by lay cadres using a rapid test at the point of care: A feasibility study in rural Lesotho.Opportunistic Invasive Mycoses in AIDS: Cryptococcosis, Histoplasmosis, Coccidiodomycosis, and Talaromycosis.HIV-Associated Cryptococcal Disease in Resource-Limited Settings: A Case for "Prevention Is Better Than Cure"?Preemptive Therapy for Cryptococcal Meningitis: A Valid Strategy for Latin America?N-acetylglucosamine affects Cryptococcus neoformans cell-wall composition and melanin architecture.Application of Culture-Independent Rapid Diagnostic Tests in the Management of Invasive Candidiasis and Cryptococcosis.CD4 Cell Count Threshold for Cryptococcal Antigen Screening of HIV-Infected Individuals: A Systematic Review and Meta-analysis.Poor specificity of urinary cryptococcal antigen testing: Reply to Drain et al. Prevalence of cryptococcal antigenuria at initial HIV diagnosis in KwaZulu-Natal.Diagnostic and therapeutic strategies in cryptococcosis: impact on outcome.
P2860
Q28078958-86BF6753-9370-466D-A808-18917A20971BQ33852819-06F1C48A-46D2-4588-B61B-C069CDBA6DDCQ36070803-0A39BE3E-86EE-418E-B048-6F90904F5A09Q36849909-EA30575D-69E1-4D65-BCEA-68219E18D320Q36900055-CDF7E1A9-E53C-46A6-8663-46CE06012437Q38785746-64D2F251-67CD-4A92-A91E-B013547F3EFDQ39559617-31552CE6-22E4-46FD-9CD9-115AE83FCD5EQ40055779-2CD65488-2250-4308-9F0C-84288E5579A2Q40074359-F01986FE-E699-4F4B-9BB2-4712D80F3AC3Q47646979-6937328E-E85D-4F93-BA44-0966FD823E37Q48520662-02835B70-1A7B-461F-B258-F2086AB2666AQ48523776-B2D19A54-0A36-488B-95A5-8C5856FAB325Q49425859-B04A82B2-1C1A-427A-9A8C-E513E1394A5FQ51365549-D8634F16-D3C4-4EB1-BAFE-342F69536E46Q51367854-E552078D-CBEB-4DB4-ACE2-702BF498885FQ55229762-4D3059CE-DCA0-4810-A710-9883DAF28231
P2860
Preventing Cryptococcosis-Shifting the Paradigm in the Era of Highly Active Antiretroviral Therapy
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Preventing Cryptococcosis-Shif ...... Active Antiretroviral Therapy
@ast
Preventing Cryptococcosis-Shif ...... Active Antiretroviral Therapy
@en
Preventing Cryptococcosis-Shif ...... Active Antiretroviral Therapy
@nl
type
label
Preventing Cryptococcosis-Shif ...... Active Antiretroviral Therapy
@ast
Preventing Cryptococcosis-Shif ...... Active Antiretroviral Therapy
@en
Preventing Cryptococcosis-Shif ...... Active Antiretroviral Therapy
@nl
prefLabel
Preventing Cryptococcosis-Shif ...... Active Antiretroviral Therapy
@ast
Preventing Cryptococcosis-Shif ...... Active Antiretroviral Therapy
@en
Preventing Cryptococcosis-Shif ...... Active Antiretroviral Therapy
@nl
P2093
P2860
P3181
P1476
Preventing Cryptococcosis-Shif ...... Active Antiretroviral Therapy
@en
P2093
David Meya
Elizabeth Nalintya
Joseph N Jarvis
Radha Rajasingham
P2860
P2888
P3181
P356
10.1007/S40475-015-0045-Z
P407
P577
2015-01-01T00:00:00Z
P5875
P6179
1029028691